Jazz Pharmaceuticals

(NASDAQ: JAZZ)
Health Care  |  Pharmaceuticals
133.02 0.0 0.0%
Stock Price | Jan. 26, 2022, 4 p.m.
1 Follower
Bid: 132.31
Ask: 136.45
Prev. Close: 133.02
52 Week Low: 117.64
52 Week High: 189.0
PE Ratio:
Dividend Yield: %

Company Summary

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Read more Read less

Recently Viewed Tickers

3 months ago

Premium Cannabis Stocks Review - AM Edition 10/06/21

3 months ago
3 months ago

Premium Cannabis Stocks Review - AM Edition 09/23/21

4 months ago
4 months ago

Premium Cannabis Stocks Review - AM Edition 08/27/21

5 months ago
5 months ago

Premium Cannabis Stocks Review - AM Edition 08/26/21

5 months ago

Premium Cannabis Stocks Review - AM Edition 08/04/21

5 months ago